Distinguished in Virilizing Ovarian Tumor

Dr. Rebecca C. Arend

Gynecologic Oncology | Obstetrics and Gynecology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
Accepting New Patients
17 Years of Experience
Distinguished in Virilizing Ovarian Tumor
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rebecca Arend is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Birmingham, Alabama. Dr. Arend has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Hysterectomy. Dr. Arend is currently accepting new patients.

Her clinical research consists of co-authoring 138 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2008
Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Other, Drug
Study Drug: Exemestane
Study Phase: Phase 2
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, DKN-01
Study Phase: Phase 2
A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer
A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab
Study Phase: Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer
Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer
Enrollment Status: Withdrawn
Publish Date: June 07, 2023
Intervention Type: Drug
Study Drug: M4344+Niraparib
Study Phase: Phase 1
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
Enrollment Status: Withdrawn
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: November 13, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

130 Total Publications

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 05, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Charles Leath
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Charles Leath
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Leath is a Gynecologic Oncologist and an Oncologist in Birmingham, Alabama. Dr. Leath is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, and Oophorectomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Warner K. Huh
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Warner K. Huh
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Warner Huh is a Gynecologic Oncologist and an Oncologist in Birmingham, Alabama. Dr. Huh is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Vaginal Cancer, Tubal Ligation, and Hysterectomy. Dr. Huh is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. John M. Straughn
Gynecologic Oncology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. John M. Straughn
Gynecologic Oncology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Straughn is a Gynecologic Oncologist and an Oncologist in Birmingham, Alabama. Dr. Straughn is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy. Dr. Straughn is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arend's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile